Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling.
| Autor: | Izzotti A; Department of Experimental Medicine, University of Genova, 16132 Genova, Italy.; IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy., Ceccaroli C; IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy., Geretto M; Department of Experimental Medicine, University of Genova, 16132 Genova, Italy., Ruggieri FG; Department of Radiotherapy, Galliera Hospital-Via, 16128 Genoa, Italy., Schenone S; Department of Health Sciences, University of Genova, 16132 Genova, Italy., Di Maria E; Department of Health Sciences, University of Genova, 16132 Genova, Italy.; Unit of Medical Genetics, Galliera Hospital, 16128 Genoa, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancers [Cancers (Basel)] 2020 Jun 22; Vol. 12 (6). Date of Electronic Publication: 2020 Jun 22. |
| DOI: | 10.3390/cancers12061652 |
| Abstrakt: | Colorectal cancer patients' responses to neoadjuvant therapy undergo broad inter-individual variations. The aim of this systematic review is to identify a molecular signature that is predictive of colon cancer downstaging and/or downgrading after neoadjuvant therapy. Among the hundreds analysed in the available studies, only 19 messenger-RNAs (mRNAs) and six micro-RNAs (miRNAs) were differentially expressed in responders versus non-responders in two or more independent studies. Therefore, a mRNA/miRNA signature can be designed accordingly, with limitations caused by the retrospective nature of these studies, the heterogeneity in study designs and the downgrading/downstaging assessment criteria. This signature can be proposed to tailor neoadjuvant therapy regimens on an individual basis. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|